908 Devices Inc Aktie News

908 Devices Inc. (NASDAQ:MASS ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Chief Executive Officer & Co-Founder Joe Griffith - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Dan Arias - Stifel Puneet Souda - Leerink Partners Brendan Smith - TD Cowen Operator Hello and welcome everyo...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025. “We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 ...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that its devices for rapid chemical detection at the point of need are being included in strategic stockpiles within Europe as part of rescEU, an EU-funded project that is establishing a reserve of disaster response capabilities. These reserves include stockpile...

BOSTON--(BUSINESS WIRE)-- #chemicalID--908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded throug...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces that it has received a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module for priority shipment in the first quarter 2025. The devices will be part of an environmental testing kit in a post-...

908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device business, expecting 11% to 15% revenue growth in 2025 with acceleration in 2026. MASS management believes losses will be significantly reduced with the new structure, with positive cash flow next year.

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety cr...

WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technolo...